BTSG — BrightSpring Health Services, Inc. Common Stock

Summary of BrightSpring Health Services, Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $3.6 billion, up 26% year-over-year.
• Pharmacy Solutions Revenue: $3.2 billion, a 25% increase.
• Provider Services Revenue: $442 million, growing 28%.
• Adjusted EBITDA: $190 million, a 45% increase, with an adjusted EBITDA margin of 5.3%, reflecting a 70 basis point improvement.
• Cash Flow from Operations: $123 million, with a leverage ratio of 2.27x, down from 2.99x at the end of 2025.
• Adjusted EPS: $0.39.

2. Strategic Updates and Business Highlights

• BrightSpring is integrating the acquired Amedisys and LHC branches, expecting approximately $30 million in EBITDA contribution in the first year.
• The company is focusing on expanding its Pharmacy Solutions, particularly in specialty and infusion services, which are seeing strong growth in script volume and patient satisfaction.
• Home Health services reported significant growth, with 49% revenue increase driven by market share gains and successful integration of acquired branches.
• The company completed the sale of its Community Living business for approximately $811 million, which will be used for debt reduction and strengthening the balance sheet.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $14.725 billion and $15.225 billion, reflecting a growth of 14.1% to 17.9% over 2025.
• Adjusted EBITDA Guidance: Projected to be between $795 million and $825 million, indicating growth of 28.7% to 33.6% over the previous year.
• The company anticipates continued growth in both Pharmacy Solutions and Provider Services, with a focus on operational efficiencies and targeted commercial strategies.

4. Bad News, Challenges, or Points of Concern

• Impact of IRA: The Home and Community Pharmacy segment is expected to face a revenue impact of approximately $175 million for the full year due to the Inflation Reduction Act (IRA).
• Generic Conversions: The company anticipates a headwind of approximately $250 million from brand-to-generic conversions.
• Competitive Pressures: Concerns regarding the increasing competition from PBMs and their push for private label biosimilars, particularly in the infusion market, though the company currently reports limited exposure to these dynamics.

5. Notable Q&A Insights

• Infusion Growth: The company reported double-digit growth in both acute and chronic specialty infusion segments, with plans to expand concierge programs for targeted therapies.
• Leverage and M&A: Management expressed a disciplined approach to potential M&A, aiming to maintain leverage under 3x while remaining open to strategic acquisitions that align with long-term goals.
• Medicare Environment: The company sees stability in the Medicare landscape, with ongoing efforts to engage in value-based care arrangements.
• Operational Efficiencies: BrightSpring is actively investing in operational improvements, including AI applications to streamline workflow and enhance efficiency across its services.

Overall, BrightSpring Health Services demonstrated strong financial performance in Q1 2026, with significant growth across its business segments, while also navigating challenges related to regulatory impacts and competitive pressures. The company remains optimistic about its strategic initiatives and future growth potential.